1. Home
  2. MANE vs IRTC Comparison

MANE vs IRTC Comparison

Compare MANE & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veradermics Incorporated Common Stock

MANE

Veradermics Incorporated Common Stock

N/A

Current Price

$126.63

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Logo iRhythm Technologies Inc.

IRTC

iRhythm Technologies Inc.

SELL

Current Price

$102.60

Market Cap

3.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MANE
IRTC
Founded
2019
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
3.7B
IPO Year
2026
2016

Fundamental Metrics

Financial Performance
Metric
MANE
IRTC
Price
$126.63
$102.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
15
Target Price
$163.50
★ $173.93
AVG Volume (30 Days)
★ 641.6K
488.8K
Earning Date
11-06-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 61.71
EPS
N/A
★ N/A
Revenue
N/A
★ $747,138,000.00
Revenue This Year
N/A
$19.25
Revenue Next Year
N/A
$15.95
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 26.24
52 Week Low
$36.26
$100.85
52 Week High
$131.24
$210.01

Technical Indicators

Market Signals
Indicator
MANE
IRTC
Relative Strength Index (RSI) 63.22 28.91
Support Level $92.62 $101.30
Resistance Level $130.52 $125.38
Average True Range (ATR) 7.99 3.85
MACD 0.49 -0.69
Stochastic Oscillator 64.33 7.84

Price Performance

Historical Comparison
MANE
IRTC

About MANE Veradermics Incorporated Common Stock

Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

About IRTC iRhythm Technologies Inc.

iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

Share on Social Networks: